Analysts at Canaccord Genuity initiated coverage on shares of Kite Pharma KITE with a Buy rating.
The target price for Kite Pharma is set to $42.
Kite Pharma's shares rose 8.33% to close at $36.16 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
